Category
GH Axis
18 articles
CJC-1295 and Ipamorelin: The Complete Combination Research Guide
A comprehensive mechanistic and protocol guide for CJC-1295 No DAC + ipamorelin combination research: orthogonal receptor pharmacology, 8–12× synergistic GH amplification, published dosing data, IGF-1 endpoints, and full study design.
GHRP-2: The Potent Growth Hormone Releasing Peptide Research Guide
A comprehensive research guide to GHRP-2: GHSR-1a pharmacology, Arvat 1997 dose-response data, cortisol/ACTH co-stimulation profile, CJC-1295 No DAC synergy, tachyphylaxis mechanisms, and full preclinical protocol design for GH axis research.
MK-677 for Sleep Quality Research: GH Pulse Architecture, SWS, and Copinschi Data
A research-focused guide to MK-677's sleep architecture effects — Copinschi 1997 polysomnography data, GHSR-1a hypothalamic sleep circuits, SWS and REM changes, EEG telemetry protocols, circadian timing, and study design considerations for sleep researchers.
Ipamorelin and Fat Loss: GHSR-1a, Lipolysis, and Body Composition Research Protocols
A comprehensive research guide to GH secretagogue-mediated lipolysis using ipamorelin: mechanism, DIO rodent study design, EchoMRI endpoints, HPA-axis sparing advantage, CJC-1295 synergy, and 6 research design considerations.
Sermorelin vs CJC-1295 No DAC vs CJC-1295 DAC: Choosing the Right GHRH Analog for Your Research
A comprehensive pharmacological comparison of the three major GHRH analog research compounds: sermorelin (GHRH 1–29), CJC-1295 No DAC (Mod GRF 1–29), and CJC-1295 with DAC. Covers mechanism, half-life, published IGF-1 data, pulsatile vs tonic GH simulation, and 6 research design considerations.
Hexarelin for Cardiac Research: GH-Independent Cardioprotection via CD36
A deep-dive into hexarelin's dual receptor pharmacology - GHSR-1a for GH secretion and CD36 scavenger receptor for GH-independent cardiac protection. Covers Bodart 1999, Torsello 2003 I/R data, DOX cardiotoxicity model, dissection designs, and preclinical dosing protocols.
Protein Synthesis and Skeletal Muscle: mTOR/S6K/eIF4E/4E-BP Pathway in GH Axis Research
A detailed research guide covering mTORC1 kinase function, S6K/4E-BP1 phosphorylation, eIF4E-mediated translation initiation, and how GH axis peptides (ipamorelin, CJC-1295, MK-677) activate the protein synthesis cascade — with preclinical dosing protocols, endpoint methods, and study design considerations.
MK-677 vs Ipamorelin vs CJC-1295: Which GH Secretagogue for Your Research?
A comparative research guide to MK-677 (ibutamoren), ipamorelin, and CJC-1295 No DAC — covering mechanisms, published IGF-1 data, half-life differences, pulsatile vs continuous GH elevation, and a decision matrix for choosing the right compound for your study design.
IGF-1 in Peptide Research: Why It's the Key Biomarker
IGF-1 is the primary endpoint for GH axis peptide research. This guide covers IGF-1 biology (GHR/JAK2/STAT5b), normal reference ranges, published IGF-1 elevation data for all major GH secretagogues, sampling timing requirements, confounders (nutrition, sex, age, stress), ELISA selection guidance, and a full research design framework for using IGF-1 as your primary endpoint.
GHRH Biology Deep Dive: Pulsatile GH Secretion, GHRHr Signaling, and Analog Research
A thorough mechanistic review of growth hormone–releasing hormone (GHRH) biology: GHRHr Gs/cAMP/PKA/CREB signaling, somatostatin counterregulation, pulsatile GH secretion, and how sermorelin, CJC-1295 No DAC, CJC-1295 DAC, and tesamorelin exploit this physiology for research applications.
GHRP Desensitization and Tachyphylaxis: What the Research Shows
A comprehensive review of GHRP receptor desensitization and tachyphylaxis: the GHSR-1a internalization mechanism via beta-arrestin-2/GRK2, published attenuation rates for ipamorelin/GHRP-2/GHRP-6/hexarelin/MK-677, washout periods, rotating GHS compound protocols, and study design implications for long-term GH axis research.
Sermorelin: GHRH Analog and Anti-Aging Research
A deep dive into sermorelin — the first 29 amino acids of GHRH, its pulsatile GH-stimulating mechanism, published RCT data on lean mass and bone density, and its role in anti-aging and GH axis research.
Hexarelin: The Forgotten GHRP with Cardiac Effects
A research-focused review of Hexarelin — a synthetic GHRH secretagogue with unique GHSR-1a and CD36 dual receptor pharmacology, superior GH release potency among GHRPs, documented cardiac cytoprotective effects, and a distinct tachyphylaxis profile that shapes research design decisions.
Tesamorelin: GHRH Analog for Visceral Fat Research
A comprehensive research guide to tesamorelin — its stabilized GHRH analog structure, FDA approval for HIV-associated lipodystrophy, published clinical data on trunk fat reduction and cardiac fat, and preclinical dosing protocols.
GHRP-2 (Pralmorelin): The Growth Hormone Releasing Peptide Research Guide
A comprehensive research review of GHRP-2 (Pralmorelin) — covering GHSR-1a binding pharmacology, GH pulse data from Arvat 1997, cortisol/ACTH activation profile, IGF-1 elevation kinetics, hunger activation mechanism, synergy with GHRH analogs, desensitization rates, and preclinical dosing protocols.
GHRP-6: The Original Ghrelin Mimetic Research Guide
A comprehensive research review of GHRP-6 — the original synthetic ghrelin mimetic. Covers GHSR-1a binding pharmacology, Bowers 1984 discovery, GH peak data, cortisol/ACTH co-activation, orexigenic appetite stimulation via NPY/AgRP, gastroprotective research data, GHRH synergy, desensitization, and preclinical SC dosing protocols.
CJC-1295 + Ipamorelin: The GH Axis Stack Deep Dive
The most-studied GH secretagogue combination in peptide research — covering dual mechanism synergy, published IGF-1 and GH pulse data, ipamorelin's selectivity advantage, pulsatile vs continuous protocols, and research design considerations for the CJC-1295 No DAC + ipamorelin stack.
Ipamorelin Dosing, Timing, and Protocol Design: A Researcher's Reference
A comprehensive research reference for ipamorelin: GHSR-1a selectivity, published dose-response data from Johansen 1999 and Arvat 1997, pulsatile timing strategies, combination protocols with CJC-1295 No DAC and MK-677, and 6-month vs 3-month research cycle considerations.